SEC Form 4 · accession 0001140361-17-000848
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Hoey
Officer — SVP, Cancer Biology & Co-CSO
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 7:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 3, 2017 | M | 12,763 | $1.43 | A | 73,742 | D | |
| Common StockF3,F2 | Jan 3, 2017 | S | 12,763 | $7.6352 | D | 60,979 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.43 | Jan 3, 2017 | M | 12,763 | D | — | Jan 11, 2017 | Common Stock | 12,763 | 0 | D |
| Stock Option (Right to Buy)F5 | $7.66 | Jan 3, 2017 | A | 55,000 | A | — | Jan 2, 2027 | Common Stock | 55,000 | 55,000 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016.
- F2Includes 27,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- F3This transaction was executed in multiple trades in prices ranging from $7.55 to $7.845, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.
- F5The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.